EVEvotec SE EVO · NASDAQ
$1.50 -2.60% (-$0.04)
- Market cap
- 487.3M €
- Enterprise value
- 614.8M €
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 0.7x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -10.4%
- Gross margin
- 10.3%
- Net margin
- -27.8%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.26
- Free float
- 94.8%
About the company
Evotec SE (EVT) is a German pharmaceutical company focused on drug research and development. The company provides services to pharmaceutical and biotechnology firms in the areas of drug discovery, testing, and drug development. Evotec collaborates with various research institutions and pharmaceutical companies worldwide to identify and develop new drugs for different diseases. The company specializes in areas such as oncology, neurology, metabolic disorders, and infectious diseases. Evotec has a long history of research and innovation in the pharmaceutical industry, and its technologies and expertise are highly regarded in the world of medical research. Evotec SE (EVT) shares may be an attractive investment opportunity for investors interested in the pharmaceutical sector and seeking an investment in a company with a significant role in discovering new drugs and therapeutic approaches.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Christian Wojczewski
Employees
4,553
Headquarters
Hamburg
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number